Cutiss: Series B Financing Round successfully secured with CHF 18.7 Mio.
News 08.06.2020 Zurich, Switzerland, June 4 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has successfully secured its series B financing round. Funds raised so far...